Core Viewpoint - The complaint against PomDoctor alleges violations of federal securities laws, including false statements and undisclosed fraudulent activities related to stock promotions and insider trading [2]. Group 1: Allegations Against PomDoctor - The complaint claims that PomDoctor was involved in a fraudulent stock promotion scheme utilizing misinformation on social media and impersonation of financial professionals [2] - It is alleged that insiders and affiliates used offshore or nominee accounts to facilitate coordinated share dumping during a price inflation campaign [2] - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [2] - As a result of these actions, the positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Proceedings - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought and is responsible for directing the litigation on behalf of the class [3] - Any member of the putative class has the option to move the court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [3] Group 3: Call for Information - Faruqi & Faruqi encourages individuals with information regarding PomDoctor's conduct, including whistleblowers and former employees, to contact the firm [4]
POM SHAREHOLDER ACTION: Faruqi & Faruqi, LLP Reminds Pomdoctor (POM) Investors of Securities Class Action Deadline on April 6, 2026